secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bicara Therapeutics Inc. (BCAX)
CIK:        0002023658
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001628280-26-009808
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicara Phase 1b data: ficerafusp alfa 2000mg Q2W shows 48% ORR, 26% CR in 1L HPV-negative HNSCC
--------------------------------------------------------------------------------

- 48% confirmed ORR and 26% complete response rate in 27 patients with 1L HPV-negative R/M HNSCC.
- 77% of responders achieved deep responses (≥80% tumor shrinkage); median time to response 1.6 months.
- Safety profile consistent with known profile of ficerafusp alfa plus pembrolizumab; generally well tolerated.
- Company plans to develop loading and every-three-week maintenance regimen pending regulatory alignment.
- Median PFS, DoR, and OS not yet estimable; data continue to mature.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023658/000162828026009808/0001628280-26-009808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023658/000162828026009808/bcax-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-009808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer